Perspective Therapeutics, Inc.CATXEarnings & Financial Report
NYSE · Health Care · Pharmaceutical Preparations
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Lantheus Holdings, Inc. | 19.90% | 116.8M | ▲ +9.16pp | 2024-03-08 |
| FMR LLC | 14.08% | 9.5M | ▲ +5.92pp | 2024-11-07 |
| S.S. OR | 7.10% | 4.8M | — | 2024-11-14 |
| Michael K Schultz | 6.30% | 17.7M | — | 2023-09-19 |
| Frances Johnson | 6.30% | 17.7M | — | 2023-09-19 |
| BlackRock, Inc. | 6.00% | 4.0M | flat | 2024-11-08 |
| NOS. OF ABOVE PERSONS | 5.30% | 3.6M | — | 2024-11-14 |
| Commodore | 4.96% | 3.4M | ▼ -1.64pp | 2024-11-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
No transactions match these filters.